---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Guidelines questions"
description: "Guidelines questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Vyndamax recommended in ATTR-CM treatment guidelines? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Guidelines questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Guidelines

<a id="vyndamax-guidelines"></a>

### Is Vyndamax recommended in ATTR-CM treatment guidelines?

> “VYNDAMAX has a Class 1 recommendation for ATTR cardiac amyloidosis in the 2022 AHA/ACC/HFSA Guidelines<sup>5</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=VYNDAMAX%20has%20a%20Class%201,amyloidosis%20in%20the%202022%20AHA%2FACC%2FHFSA)

> “VYNDAMAX is recommended for ATTR cardiac amyloidosis in the ACC 2025 Concise Clinical Guidance<sup>6</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=VYNDAMAX%20is%20recommended%20for%20ATTR,the%20ACC%202025%20Concise%20Clinical)

> “Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.
> Kittleson MM, Ambardekar AV, Cheng RK, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol. Published online October 31, 2025. doi:10.1016/j.jacc.2025.09.004”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=Heidenreich%20PA%2C%20Bozkurt%20B%2C%20Aguilar,online%20October%2031%2C%202025.%20doi%3A10.1016%2Fj.jacc.2025.09.004)

Note: Both statements are the manufacturer's summaries on the Vyndamax HCP efficacy page; the guideline texts, including the population and level of evidence of each recommendation, were not captured. The 2022 document is a heart failure guideline, and the 2025 document is an ACC concise clinical guidance on transthyretin cardiac amyloidosis.

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
